Eligibility Colorectal Cancer Metastatic NCT01943786

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis of stage iv colorectal adenocarcinoma.
Description

ID.1

Data type

boolean

patient ≥ 18 years of age.
Description

ID.2

Data type

boolean

ecog ps 0-1
Description

ID.3

Data type

boolean

life expectancy ≥ 6 months
Description

ID.4

Data type

boolean

candidate for first-line systemic chemotherapy according to regular clinical practice.
Description

ID.5

Data type

boolean

measurable disease.
Description

ID.6

Data type

boolean

wild-type kras
Description

ID.7

Data type

boolean

signed informed consent form.
Description

ID.8

Data type

boolean

Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patient who has received prior chemotherapy for metastatic crc, except for adjuvant treatment completed at least six months before entering study.
Description

ID.9

Data type

boolean

patient in whom there is a contraindication for the use of any of the drugs used in first-line treatment of colorectal cancer: 5-fluorouracil,, irinotecan or cetuximab
Description

ID.10

Data type

boolean

Similar models

Eligibility Colorectal Cancer Metastatic NCT01943786

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
diagnosis of stage iv colorectal adenocarcinoma.
boolean
ID.2
Item
patient ≥ 18 years of age.
boolean
ID.3
Item
ecog ps 0-1
boolean
ID.4
Item
life expectancy ≥ 6 months
boolean
ID.5
Item
candidate for first-line systemic chemotherapy according to regular clinical practice.
boolean
ID.6
Item
measurable disease.
boolean
ID.7
Item
wild-type kras
boolean
ID.8
Item
signed informed consent form.
boolean
Item Group
C0680251 (UMLS CUI)
ID.9
Item
patient who has received prior chemotherapy for metastatic crc, except for adjuvant treatment completed at least six months before entering study.
boolean
ID.10
Item
patient in whom there is a contraindication for the use of any of the drugs used in first-line treatment of colorectal cancer: 5-fluorouracil,, irinotecan or cetuximab
boolean